Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Nanotechnology Victoria (NanoVic) was an Australian commercialization vehicle established to bridge the gap between nanotechnology research and industrial application. Formed as a joint venture between Monash University, Swinburne University of Technology, RMIT University, and the Victorian State Government, the company focused on developing and licensing nano-enabled technologies. Its portfolio spanned several sectors, with significant emphasis on life sciences, including drug delivery systems, diagnostic tools, and antimicrobial coatings. NanoVic played a pivotal role in the Victorian nanotechnology ecosystem by providing funding, intellectual property management, and business development expertise to early-stage ventures before its operations were wound down and integrated into its partner institutions.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Nanotechnology Victoria.